ZA200703453B - Compositions and methods for short interfering nucleic acid inhibition of Nav 1.8 - Google Patents
Compositions and methods for short interfering nucleic acid inhibition of Nav 1.8 Download PDFInfo
- Publication number
- ZA200703453B ZA200703453B ZA200703453A ZA200703453A ZA200703453B ZA 200703453 B ZA200703453 B ZA 200703453B ZA 200703453 A ZA200703453 A ZA 200703453A ZA 200703453 A ZA200703453 A ZA 200703453A ZA 200703453 B ZA200703453 B ZA 200703453B
- Authority
- ZA
- South Africa
- Prior art keywords
- seq
- short interfering
- interfering nucleic
- nucleic acid
- sirna
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims description 167
- 102000039446 nucleic acids Human genes 0.000 title claims description 155
- 108020004707 nucleic acids Proteins 0.000 title claims description 155
- 230000002452 interceptive effect Effects 0.000 title claims description 130
- 238000000034 method Methods 0.000 title claims description 57
- 239000000203 mixture Substances 0.000 title claims description 17
- 230000005764 inhibitory process Effects 0.000 title description 3
- 239000011734 sodium Substances 0.000 claims description 140
- 239000002773 nucleotide Substances 0.000 claims description 54
- 125000003729 nucleotide group Chemical group 0.000 claims description 53
- 108020004999 messenger RNA Proteins 0.000 claims description 48
- 208000002193 Pain Diseases 0.000 claims description 39
- 230000000692 anti-sense effect Effects 0.000 claims description 23
- 239000013598 vector Substances 0.000 claims description 20
- 208000000094 Chronic Pain Diseases 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 108091081021 Sense strand Proteins 0.000 claims description 17
- 239000012528 membrane Substances 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 15
- 229910052708 sodium Inorganic materials 0.000 claims description 15
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 230000000903 blocking effect Effects 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 11
- 108020004635 Complementary DNA Proteins 0.000 claims description 10
- 238000013519 translation Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 162
- 210000004027 cell Anatomy 0.000 description 137
- 108090000623 proteins and genes Proteins 0.000 description 38
- 229920002477 rna polymer Polymers 0.000 description 37
- 238000004020 luminiscence type Methods 0.000 description 28
- 108010052164 Sodium Channels Proteins 0.000 description 24
- 241000700159 Rattus Species 0.000 description 22
- 102000018674 Sodium Channels Human genes 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 20
- 230000009368 gene silencing by RNA Effects 0.000 description 19
- 238000003197 gene knockdown Methods 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 16
- 208000014674 injury Diseases 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 14
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 14
- 239000013613 expression plasmid Substances 0.000 description 14
- 239000013603 viral vector Substances 0.000 description 14
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 230000006378 damage Effects 0.000 description 13
- 230000030279 gene silencing Effects 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 230000015556 catabolic process Effects 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 12
- 238000006731 degradation reaction Methods 0.000 description 12
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 11
- 229950010357 tetrodotoxin Drugs 0.000 description 11
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 208000004296 neuralgia Diseases 0.000 description 10
- 208000021722 neuropathic pain Diseases 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108091006146 Channels Proteins 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 8
- 208000004454 Hyperalgesia Diseases 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 210000003594 spinal ganglia Anatomy 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 6
- 206010053552 allodynia Diseases 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002981 neuropathic effect Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 4
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 4
- 101710134422 Sodium channel protein type 10 subunit alpha Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000000548 hind-foot Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 101150050629 1.8 gene Proteins 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 206010001497 Agitation Diseases 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 3
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 3
- 241000906446 Theraps Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 210000000578 peripheral nerve Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- IQFYYKKMVGJFEH-BIIVOSGPSA-N 2'-deoxythymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-BIIVOSGPSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 206010049119 Emotional distress Diseases 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010029174 Nerve compression Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 206010037779 Radiculopathy Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 208000008765 Sciatica Diseases 0.000 description 2
- 102100033974 Sodium channel protein type 11 subunit alpha Human genes 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 2
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000002779 membrane potential assay Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 210000001044 sensory neuron Anatomy 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 239000003195 sodium channel blocking agent Substances 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000001032 spinal nerve Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000000427 trigeminal ganglion Anatomy 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010065952 Hyperpathia Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 241000158500 Platanus racemosa Species 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101000640025 Rattus norvegicus Sodium channel protein type 10 subunit alpha Proteins 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101150110009 SCN11A gene Proteins 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- MMXKIWIWQPKTIK-KPRKPIBOSA-N [(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl [(2r,3s,5r)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-2-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)[C@@H](O)C1 MMXKIWIWQPKTIK-KPRKPIBOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 210000003766 afferent neuron Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- -1 ribonucleoside phosphoramidites Chemical class 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62248404P | 2004-10-27 | 2004-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200703453B true ZA200703453B (en) | 2008-06-25 |
Family
ID=36061603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200703453A ZA200703453B (en) | 2004-10-27 | 2007-04-26 | Compositions and methods for short interfering nucleic acid inhibition of Nav 1.8 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US7786291B2 (ja) |
| EP (2) | EP1809745A2 (ja) |
| JP (3) | JP2008517629A (ja) |
| KR (1) | KR20070083828A (ja) |
| CN (2) | CN102352355A (ja) |
| AR (1) | AR051829A1 (ja) |
| AU (1) | AU2005299310A1 (ja) |
| CA (1) | CA2584785A1 (ja) |
| IL (1) | IL182680A0 (ja) |
| MX (1) | MX2007005069A (ja) |
| NO (1) | NO20072692L (ja) |
| SG (1) | SG158921A1 (ja) |
| WO (1) | WO2006047687A2 (ja) |
| ZA (1) | ZA200703453B (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7582745B2 (en) * | 2005-11-04 | 2009-09-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Nav1.8 gene |
| WO2009033027A2 (en) * | 2007-09-05 | 2009-03-12 | Medtronic, Inc. | Suppression of scn9a gene expression and/or function for the treatment of pain |
| BRPI0913644A2 (pt) | 2008-06-30 | 2015-11-24 | Janssen Pharmaceutica Nv | processo para a prepração de derivados de pirimidina substituída. |
| UA109220C2 (uk) * | 2011-10-26 | 2015-07-27 | Пфайзер Лімітед | Похідні (4-фенілімідазол-2-іл)етиламіну як модулятори натрієвих каналів |
| TWI516593B (zh) * | 2012-06-11 | 2016-01-11 | 義守大學 | 一種聚核苷酸用以製備減緩疼痛藥物之用途 |
| AU2014255381A1 (en) | 2013-04-17 | 2015-10-08 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| CN107735140B (zh) * | 2015-05-11 | 2021-04-20 | 亚克安娜生命科学有限公司 | 药物输送系统和方法 |
| CA3045135A1 (en) | 2016-12-21 | 2018-06-28 | Alcyone Lifesciences, Inc. | Drug delivery systems and methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9513180D0 (en) * | 1995-06-28 | 1995-08-30 | Univ London | Ion channel |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AU2001245793A1 (en) * | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
| DK2796553T3 (da) * | 2000-03-30 | 2019-09-30 | Whitehead Inst Biomedical Res | Rna-sekvensspecifikke formidlere af rna-interferens |
| ES2728168T3 (es) * | 2000-12-01 | 2019-10-22 | Max Planck Gesellschaft | Moléculas pequeñas de ARN que median en la interferencia de ARN |
| GB0120238D0 (en) * | 2001-08-20 | 2001-10-10 | Univ College Of London | Sodium channel regulators and modulators |
| US20060030534A1 (en) * | 2002-09-04 | 2006-02-09 | Gabriele Dorn | Treatment of neurological disorders by dsrna administration |
| WO2004087956A2 (en) * | 2003-04-02 | 2004-10-14 | Ionix Pharmaceuticals Limited | Cell lines for the functional expression of nav1.8 |
| EP3604537B1 (en) | 2003-06-13 | 2021-12-08 | Alnylam Europe AG | Double-stranded ribonucleic acid with increased effectiveness in an organism |
| US7341835B2 (en) * | 2004-01-13 | 2008-03-11 | Affymetrix, Inc. | Methods of analysis of alternative splicing in mouse |
-
2005
- 2005-10-26 US US11/259,588 patent/US7786291B2/en not_active Expired - Fee Related
- 2005-10-26 KR KR1020077009578A patent/KR20070083828A/ko not_active Application Discontinuation
- 2005-10-26 EP EP05825147A patent/EP1809745A2/en not_active Withdrawn
- 2005-10-26 EP EP10011470A patent/EP2371954A1/en not_active Withdrawn
- 2005-10-26 AR ARP050104492A patent/AR051829A1/es not_active Application Discontinuation
- 2005-10-26 CN CN2011102887035A patent/CN102352355A/zh active Pending
- 2005-10-26 SG SG201000580-9A patent/SG158921A1/en unknown
- 2005-10-26 CN CN2005800450905A patent/CN101103112B/zh not_active Expired - Fee Related
- 2005-10-26 CA CA002584785A patent/CA2584785A1/en not_active Abandoned
- 2005-10-26 JP JP2007539118A patent/JP2008517629A/ja not_active Withdrawn
- 2005-10-26 AU AU2005299310A patent/AU2005299310A1/en not_active Abandoned
- 2005-10-26 MX MX2007005069A patent/MX2007005069A/es active IP Right Grant
- 2005-10-26 WO PCT/US2005/038792 patent/WO2006047687A2/en active Application Filing
-
2007
- 2007-04-19 IL IL182680A patent/IL182680A0/en unknown
- 2007-04-26 ZA ZA200703453A patent/ZA200703453B/en unknown
- 2007-05-25 NO NO20072692A patent/NO20072692L/no not_active Application Discontinuation
-
2010
- 2010-05-28 US US12/789,564 patent/US8309703B2/en not_active Expired - Fee Related
- 2010-09-06 JP JP2010199379A patent/JP2011015695A/ja not_active Withdrawn
-
2012
- 2012-10-16 US US13/653,013 patent/US8729045B2/en not_active Expired - Fee Related
-
2013
- 2013-05-10 JP JP2013100220A patent/JP2013176386A/ja active Pending
-
2014
- 2014-04-22 US US14/258,391 patent/US20140256787A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013176386A (ja) | 2013-09-09 |
| US20060199779A1 (en) | 2006-09-07 |
| CN101103112B (zh) | 2011-11-16 |
| AU2005299310A1 (en) | 2006-05-04 |
| CA2584785A1 (en) | 2006-05-04 |
| WO2006047687A2 (en) | 2006-05-04 |
| US8309703B2 (en) | 2012-11-13 |
| NO20072692L (no) | 2007-05-25 |
| US20140256787A1 (en) | 2014-09-11 |
| US20100305192A1 (en) | 2010-12-02 |
| JP2011015695A (ja) | 2011-01-27 |
| US20130109739A1 (en) | 2013-05-02 |
| AR051829A1 (es) | 2007-02-14 |
| JP2008517629A (ja) | 2008-05-29 |
| MX2007005069A (es) | 2007-06-25 |
| EP1809745A2 (en) | 2007-07-25 |
| WO2006047687A3 (en) | 2006-07-06 |
| US8729045B2 (en) | 2014-05-20 |
| SG158921A1 (en) | 2010-02-26 |
| IL182680A0 (en) | 2007-09-20 |
| US7786291B2 (en) | 2010-08-31 |
| CN102352355A (zh) | 2012-02-15 |
| CN101103112A (zh) | 2008-01-09 |
| EP2371954A1 (en) | 2011-10-05 |
| KR20070083828A (ko) | 2007-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8729045B2 (en) | Compositions and methods for short interfering nucleic acid inhibition of Nav1.8 | |
| US10000753B2 (en) | Age-related macular degeneration treatment | |
| US9518260B2 (en) | Pain treatment | |
| US8183221B2 (en) | Suppression of SCN9A gene expression and/or function for the treatment of pain | |
| BRPI0621264A2 (pt) | inibição mediada por rnai de rho quinase para o tratamento de distúrbios oculares | |
| KR20090042297A (ko) | ＩＯＰ―관련 증상을 치료하기 위한 그렘린의 ＲＮＡｉ 매개 억제 | |
| US20110190376A1 (en) | RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA | |
| CA2632690C (en) | Rnai-mediated inhibition of igf1r for treatment of ocular angiogenesis | |
| EP1899468B1 (en) | siRNA FOR INHIBITING IL-6 EXPRESSION AND COMPOSITION CONTAINING THEM | |
| US20090060889A1 (en) | Ii-RNAi involved Ii suppression in cancer immunotherapy | |
| US20210332364A1 (en) | siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOF | |
| TW200808328A (en) | RNAi-mediated inhibition of stromal cell-derived factor 1-related targets for treatment of neovascularization-related conditions | |
| WO2024036343A2 (en) | Synergistic nucleic acid based therapeutics and methods of use for treating genetic disorders | |
| WO2018141025A1 (en) | Reagents for treatment of ocular diseases and conditions associated with neovascularisation and use thereof | |
| WO2018130518A1 (en) | Methods and pharmaceutical composition for inducing senescence in cancer cells |